{"data":[{"attributes":{"attrs":{},"content":{"blocks":[{"classNames":{},"fields":{"image":"54beade6-82ec-4731-be81-d642cd944796","subTitle":"of cyclotron-produced actinium-225","title":"Ensuring a steady supply"},"hidden":false,"id":14738742,"label":"Hero","protected":true,"repeatableFields":[]},{"classNames":{"bg-color":false},"fields":[{"image":"","link":"","text":"

AlfaRim’s innovative technology for the industrialised production of actinium-225 (Ac-225) is based on the physical Ra-226(p,2n)Ac-225 reaction: bombarding radium-226 (Ra-226) with protons generated by a medical cyclotron, in order to produce high quantities of cGMP-grade Ac-225 at significantly lower costs.

","title":"About our technology","video":""},{"image":"1033fb66-f0e3-4396-b4eb-5e4b2b2fb0c0","link":"","text":"

","title":"","video":""}],"hidden":false,"id":51569358,"label":"TwoColumns","protected":false,"repeatableFields":[]},{"classNames":{},"fields":{"image":"","link":"","text":"

We will produce Ac-225 in our own state-of-the-art medical isotope production facility in Delft, the Netherlands. In one of our hot labs, Ra-226 will be mounted on a solid target that is then placed in front of a beamline in a target irradiation bunker. Our cyclotron will generate protons with an energy of up to 18 MeV, which exit through the beamline towards the Ra-226 target.

The target is irradiated for a set amount of time. Due to the massive impact of the proton bombardment, single protons enter the nucleus of Ra-226 atoms, causing those atoms to become excited and unstable. In order to reach a (more) stable state, the excited Ra-226 atoms eject two neutrons from their nuclei, thereby transforming themselves into a different element: Ac-225. Due to the low conversion rate of Ra-226 to Ac-225, the remaining Ra-226 is unaffected and can be reused again and again, making AlfaRim’s production process highly sustainable.

","title":"Ra-226(p,2n)Ac-225 reaction explained"},"hidden":false,"id":76921288,"label":"OneColumn","protected":false,"repeatableFields":[]},{"classNames":{},"fields":{"image":"","link":"","text":"

Ac-225 demand for clinical research alone is currently estimated at 50.000 millicuries (mCi) per year. However, today’s worldwide supply is no more than 4.900 mCi per year. AlfaRim has secured its own Ra-226 stock and based on its innovative production technology we will be capable of producing large quantities of Ac-225 and supply it to customers ranging from a single patient dose to multi-patient bulk doses.

","title":"Large scale production and continuous supply of Ac-225"},"hidden":false,"id":60638651,"label":"OneColumn","protected":false,"repeatableFields":[]},{"classNames":{"bg-color":true,"center-align":true,"smaller-size":true},"fields":{"title":""},"hidden":false,"id":53672764,"label":"GradientBlock","protected":false,"repeatableFields":[{"image":"ea35de26-3dfb-4109-af8f-48ff4ba034ed","imageTitle":"of actinium-225 per year"},{"image":"cf86cb60-0aa4-4e65-8ec0-804314c7e92d","imageTitle":"of current estimated global demand"},{"image":"b5e5e7b4-73eb-4311-bdc4-1eb7b010e828","imageTitle":"the current global production"}]},{"classNames":{},"fields":[{"image":"5b86d4ca-d6d5-4123-92da-3044199dd0d3","link":"","text":"","title":"","video":""},{"image":"","link":"","text":"

Our state-of-the-art medical isotope production facility, dedicated to the supply of cGMP-grade Ac-225

AlfaRim is currently developing a brand-new radiopharmaceutical production facility on the Delft University of Technology (TU Delft) Campus, directly opposite the Holland Proton Therapy Center (Holland PTC) and the nuclear reactor of the Reactor Institute Delft (RID).

","title":"The AlfaRim Facility","video":""}],"hidden":false,"id":82820555,"label":"TwoColumns","protected":false,"repeatableFields":[]},{"classNames":{},"fields":[{"image":"","link":"","text":"

The facility will house several hot labs authorised to handle alpha isotopes. Targets will be manufactured in our dedicated Radium lab, from which they are automatically transported to one of the two target irradiation bunkers connected to our cyclotron. Ac-225 will be dispensed under cGMP-qualifications at our Actinium lab. The pre-calibrated final product – ranging from patient doses to bulk volumes for central labelling at clients’ facilities – will be packed in our isotope packaging and logistics labs.

","title":"Production labs","video":""},{"image":"70acd2d1-2488-4426-b386-b41ef840608d","link":"","text":"","title":"","video":""}],"hidden":false,"id":9200385,"label":"TwoColumns","protected":false,"repeatableFields":[]},{"classNames":{},"fields":[{"image":"429618ee-a559-4ac4-a47f-2f39ba2ed8a3","link":"","text":"","title":"","video":""},{"image":"","link":"","text":"

Besides production labs, the facility will also house an R&D lab with access to the cyclotron. This lab will be used for AlfaRim’s own research into novel radioisotopes. Alternatively, this lab can be used to test (future) clients’ targeting molecules with AlfaRim’s Ac-225. It can also function as an Open Innovation Test Bed, where external parties (academic, scientific, corporate, etc.) can rent “beam-time”.

","title":"R&D lab","video":""}],"hidden":false,"id":91060067,"label":"TwoColumns","protected":false,"repeatableFields":[]}],"redirect":""},"discoverable":true,"locale":null,"menu":{"main":true},"position":{"main":0},"publishAt":"2021-06-29T22:03:39Z","related":{"document":[],"locales":{},"media":["54beade6-82ec-4731-be81-d642cd944796","8d26ae95-69ff-4c4d-8593-6c6b2896e839","a22f9702-3b79-481c-9096-51db8dea3c82","cbd6d060-b167-4785-bc20-241d885f8874","bf348f28-61ff-4dbb-ac35-f5aaea312180","8835eac6-96fd-458f-a234-f0efcb86cb27","2b1da7d3-bdf8-4604-9c5b-2a14b219b55c","88026642-dbfa-452f-9b83-9e7a259d2cb6","6d6f531d-36fe-4e34-a017-3c128b479710","1033fb66-f0e3-4396-b4eb-5e4b2b2fb0c0","d9e2b615-c09c-44b6-96e0-52b5de1ab4d5","9d589154-b58a-43a6-b0c8-354945b7b5ec","f87096a5-09d9-4b7e-862a-1ba7ea7694b2","bd034652-440f-4616-845f-68fa32305361","de95333b-74b1-45db-8202-8863fe6de3a2","f7d605c2-fdb0-40ce-80d0-8bcff9eaa8a4","5d874a69-dbf1-49db-aedc-e447c62ecb8b","ea35de26-3dfb-4109-af8f-48ff4ba034ed","cf86cb60-0aa4-4e65-8ec0-804314c7e92d","b5e5e7b4-73eb-4311-bdc4-1eb7b010e828","afe17ad0-80bf-406e-9800-995b7efe9fef","5477cb84-308f-4530-b0bc-af2ddc511ec7","70acd2d1-2488-4426-b386-b41ef840608d","429618ee-a559-4ac4-a47f-2f39ba2ed8a3","5b86d4ca-d6d5-4123-92da-3044199dd0d3"]},"slug":"technology","template":"standard","title":"Technology"},"id":"717f404d-d555-47b6-90d3-52b9fed15f1a","relationships":{"children":{"data":[]}},"type":"document"},{"attributes":{"attrs":{},"content":{"blocks":[{"classNames":{},"fields":{"image":"bf348f28-61ff-4dbb-ac35-f5aaea312180","subTitle":"Accelerating targeted alpha therapy","title":"Actinium-225"},"hidden":false,"id":51923709,"label":"Hero","protected":true,"repeatableFields":[]},{"classNames":{},"fields":[{"image":"","link":"","text":"

Actinium-225 (Ac-225) is an isotope of actinium, with a half-life of approximately 10 days. It is used in nuclear medicine for the treatment of cancer. Ac-225 and its decay products emit alpha particles. Ac-225 has a high cytotoxic potency within a very short range, enabling it to destroy cancerous cells in the body while sparing surrounding healthy tissues. This makes it the “isotope of choice” for Targeted Alpha Therapy.

","title":"Actinium-225","video":""},{"image":"8daed258-50a6-4619-a7b0-13c8a68c977c","link":"","text":"","title":"","video":""}],"hidden":false,"id":48713605,"label":"TwoColumns","protected":false,"repeatableFields":[]},{"classNames":{},"fields":{"image":"","link":"","text":"

Cancer treatments have evolved significantly in recent years, and the focus of current clinical research studies is on developing more targeted therapies. Today, targeted radiotherapies solely make use of so-called beta isotopes (such as Lutetium-177). However, novel and breakthrough clinical research has proven that targeted therapies that use alpha isotopes are much more effective when it comes to actually destroying the cancer cell. We speak of Targeted Alpha Therapy (or TAT) when an alpha isotope, such as Ac-225, is labelled to a targeting molecule.

By providing the radiopharmaceutical industry with Ac-225, AlfaRim will facilitate the breakthrough and further development of targeted alpha therapies. As a new mainstream treatment, actinium-based targeted alpha therapy will provide a groundbreaking treatment for numerous cancer types.

","title":"Targeted Alpha Therapy"},"hidden":false,"id":30344637,"label":"OneColumn","protected":false,"repeatableFields":[]},{"classNames":{"bg-color":true},"fields":{"title":"Alpha therapies can be used to combat the following types of cancer: "},"hidden":false,"id":6482054,"label":"GradientBlock","protected":false,"repeatableFields":[{"image":"4cb4602c-2ef1-4bf7-ac32-680bb8f25dfb","imageTitle":""},{"image":"6bab1c9c-b66a-4807-91cf-02b8ba09200d","imageTitle":""},{"image":"0037ca9e-b5f4-4d49-9d75-9856964270e3","imageTitle":""}]},{"classNames":{},"fields":[{"image":"95725bef-7120-46eb-a506-33e7ab263f3c","link":"","text":"","title":"","video":""},{"image":"","link":"","text":"

Alpha isotopes are the most effective at causing double-strand breaks in DNA molecules. This is essential, because the best way to destroy a malignant tumour is to completely eliminate each cell that makes up the cancer by disrupting and breaking up its DNA.

","title":"Breaking up the DNA","video":""}],"hidden":false,"id":24920205,"label":"TwoColumns","protected":false,"repeatableFields":[]}],"redirect":""},"discoverable":true,"locale":null,"menu":{"main":true},"position":{"main":1},"publishAt":"2021-06-30T08:13:39Z","related":{"document":[],"locales":{},"media":["54beade6-82ec-4731-be81-d642cd944796","bf348f28-61ff-4dbb-ac35-f5aaea312180","8262e2e8-4ed5-453e-9c3a-cbc2bbbfb7b0","95725bef-7120-46eb-a506-33e7ab263f3c","8b82b18b-17fe-4ace-95a1-ab66cdf42a29","2c896a28-3ca4-4e19-88c1-da09e6ddee4e","e31940a0-cc57-42ef-9be9-e5b34ddfe636","8e252589-a2f8-4dc5-a02c-14d549d613e7","e603e5cd-9ff5-45c3-ac88-6be9897529dc","fdff0403-1c51-4d58-a01e-0f654080eed0","900552d0-b39a-47d1-b175-f7da0f1861ec","8daed258-50a6-4619-a7b0-13c8a68c977c","0037ca9e-b5f4-4d49-9d75-9856964270e3","ae4a4eca-aab4-4b92-ac41-280a6b3ec133","3197ad75-f576-45f9-9d59-52dad1f74133","4cb4602c-2ef1-4bf7-ac32-680bb8f25dfb","6bab1c9c-b66a-4807-91cf-02b8ba09200d","c75e0988-722a-47a3-a337-7e7e05a97cf0","5fe6fe1b-8167-433e-94c1-0225f9dda6e1"]},"slug":"application","template":"standard","title":"Application"},"id":"fbbd0bc8-5901-4a19-82f3-60a08b153aae","relationships":{"children":{"data":[]}},"type":"document"},{"attributes":{"attrs":{},"content":{"blocks":[{"classNames":{},"fields":{"image":"f663ee31-bfd3-471d-9c90-f15364a19a91","subTitle":"by supplying actinium-225 to the radiopharmaceutical industry","title":"Our ambition is to cure cancer"},"hidden":false,"id":69879644,"label":"Hero","protected":true,"repeatableFields":[]},{"classNames":{},"fields":{"image":"","link":"","text":"

AlfaRim is a deep tech start-up company in the field of medical isotope production. We have developed an innovative process technology for the production of the medical isotope of choice: actinium-225 (Ac-225). We apply a holistic approach in the development of our state-of-the-art radiopharmaceutical facility for the large-scale production of cGMP-grade Ac-225. We excel when it comes to the intricacies of radioisotope production, and our technology will guarantee a continuous supply of Ac-225. This will make us a leading supplier – and your trustworthy partner.

","title":"About us"},"hidden":false,"id":73476667,"label":"OneColumn","protected":false,"repeatableFields":[]},{"classNames":{"bg-color":false},"fields":[{"image":"","link":"","text":"

At AlfaRim, we believe in a world where people no longer die from cancer or suffer unnecessarily during their treatment; a world where a cure can be found through the right combination of ingenuity, therapy and medication. Our ambition is to cure cancer.

","title":"Why we do it"},{"image":"","link":"","text":"

We believe that Targeted Alpha Therapy is the right method for curing cancer. By supplying Ac-225 to the radiopharmaceutical industry, we will
1) allow existing clinical research initiatives on Targeted Alpha Therapy to come into maturity, and
2) pave the way for Targeted Alpha Therapy to become a mainstream therapy for the treatment of many types of cancer.

","title":"How we do it"},{"image":"","link":"","text":"

Therefore, we will make cGMP-grade, cyclotron-produced Ac-225 available in large quantities for acceptable prices. Straight from our production facility in Delft, the Netherlands, we will offer a worldwide supply of Ac-225 – in predictable quantities and at predictable moments in time.

","title":"What we do"}],"hidden":false,"id":38549249,"label":"ThreeColumns","protected":false,"repeatableFields":[{"image":"","link":"","text":"

At Alfarim we believe in a world in which people no longer need to die from cancer or suffer unnecessarily during their treatment: a world where a cure can be found through the right combination of ingenuity, therapy and medication. It is our ambition to cure cancer.

","title":"Why we do it"},{"image":"","link":"","text":"

A targeted therapy which uses Alpha emitters instead of Beta- or Chemo emitters. A therapy which is still in it's early childhood stage but is rapidly gaining attention for its potential effectiveness. We believe that Targeted Alpha Therapy is the method for curing cancer.

","title":"How we do it"},{"image":"","link":"","text":"

We make Actinium-225 available in sufficient quantities for acceptable prices. Because of this we: 1. Allow existing clinical research initiatives on Targeted Alpha Therapy to come into maturity, and 2. Open the way towards Targeted Alpha Therapy becoming a mainstream therapy for the treatment of many types of cancer.

","title":"What we do"}]},{"classNames":{"bg-color":true},"fields":{"team":"","text":"

A multi-disciplined management team with almost 70 years of combined experience in nuclear medicine, applied physics, engineering, finance and management.

","title":"Our team"},"hidden":false,"id":91989256,"label":"TeamOverview","protected":false,"repeatableFields":[]}],"redirect":""},"discoverable":true,"locale":null,"menu":{"main":true},"position":{"main":2},"publishAt":"2021-06-29T21:58:24Z","related":{"document":[],"locales":{},"media":["ae3093c8-4778-4e2c-baaf-490114d8b690","bf348f28-61ff-4dbb-ac35-f5aaea312180","c63e9143-aa0d-42af-9d88-33207bddbbb4","8daed258-50a6-4619-a7b0-13c8a68c977c","900552d0-b39a-47d1-b175-f7da0f1861ec","4a0da4d4-b284-4ad7-9ce2-acd7e2e139fa","a5a7d2aa-d4c8-4b00-937b-92b8cee95a2c","d49cc57d-cb56-4f82-b555-4d821e6d397c","3bef8c06-292a-4321-82d4-88707bb7d4d9","7688361c-cfed-4ace-84df-614e8c7674b6","0aaac28b-73e9-4072-ac19-e59b93e1e41c","b44bd48a-545f-4c1f-8e5d-a38bb723ee39","c1b072f7-471e-41e9-a8b9-09d59d522a16","f663ee31-bfd3-471d-9c90-f15364a19a91"]},"slug":"about","template":"standard","title":"About"},"id":"978afeea-64da-4289-b344-2c73e8190208","relationships":{"children":{"data":[]}},"type":"document"},{"attributes":{"attrs":{},"content":{"blocks":[{"classNames":{},"fields":{"image":"8835eac6-96fd-458f-a234-f0efcb86cb27","subTitle":"to make next-generation cancer therapies possible","title":"Join our mission"},"hidden":false,"id":61921170,"label":"Hero","protected":true,"repeatableFields":[]},{"classNames":{},"fields":[{"image":"","link":{"custom":"https://www.google.com/maps/place/Molengraaffsingel+12,+2629+JD+Delft/data=!4m2!3m1!1s0x47c5ca77f340ca97:0x39de62280f074290?sa=X&ved=2ahUKEwiI0uqa4brzAhUHCewKHefXBesQ8gF6BAgLEAE","document":null,"hook":null,"media":null,"title":"Get directions"},"text":"

Molengraaffsingel 12
2629 JD Delft
The Netherlands
info@alfarim.com

","title":"Contact us","video":""},{"image":"21389e14-67e8-4e03-ac8f-2123af4e4a53","link":"","text":"","title":"","video":""}],"hidden":false,"id":37463460,"label":"TwoColumns","protected":false,"repeatableFields":[]},{"classNames":{},"fields":{"text":"

Please contact us at info@alfarim.com or fill out the contact form and we will contact you as soon as possible.

","title":"Want to know more?"},"hidden":false,"id":81880724,"label":"Contact","protected":false,"repeatableFields":[]}],"redirect":""},"discoverable":true,"locale":null,"menu":{"main":true},"position":{"main":3},"publishAt":"2021-06-30T08:15:01Z","related":{"document":[],"locales":{},"media":["8835eac6-96fd-458f-a234-f0efcb86cb27","21389e14-67e8-4e03-ac8f-2123af4e4a53"]},"slug":"contact","template":"standard","title":"Contact"},"id":"81f586f5-1d64-4f8d-b91a-a3dccac47f11","relationships":{"children":{"data":[]}},"type":"document"}],"included":[],"meta":{"related":{"document":{"data":[],"included":[]},"media":{"data":[{"attributes":{"contentType":"image/jpeg","filename":"20-069 Paul_Michielsen_Alfarim_Delft_Frame0000_H.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"20-069 Paul_Michielsen_Alfarim_Delft_Frame0000_H.jpg"},"id":"5477cb84-308f-4530-b0bc-af2ddc511ec7","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"aangepast-alfarim-plaatje-01.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"aangepast-alfarim-plaatje-01.jpg"},"id":"f663ee31-bfd3-471d-9c90-f15364a19a91","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"IMG_5134.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"IMG_5134.jpg"},"id":"5b86d4ca-d6d5-4123-92da-3044199dd0d3","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"aangepast-alfarim-plaatje-02.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"aangepast-alfarim-plaatje-02.jpg"},"id":"c75e0988-722a-47a3-a337-7e7e05a97cf0","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"IMG_5133.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"IMG_5133.jpg"},"id":"70acd2d1-2488-4426-b386-b41ef840608d","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"IMG_5135.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"IMG_5135.jpg"},"id":"429618ee-a559-4ac4-a47f-2f39ba2ed8a3","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"IMG_5137.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"IMG_5137.jpg"},"id":"5fe6fe1b-8167-433e-94c1-0225f9dda6e1","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"alpharim cell2_0114.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"alpharim cell2_0114.png"},"id":"1033fb66-f0e3-4396-b4eb-5e4b2b2fb0c0","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"malebody screenshot0064.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"malebody screenshot0064.png"},"id":"8daed258-50a6-4619-a7b0-13c8a68c977c","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"body_i2_0020.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"body_i2_0020.png"},"id":"fdff0403-1c51-4d58-a01e-0f654080eed0","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"screenshot-map.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"screenshot-map.jpg"},"id":"21389e14-67e8-4e03-ac8f-2123af4e4a53","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"example-image4.jpeg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"example-image4.jpeg"},"id":"95725bef-7120-46eb-a506-33e7ab263f3c","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"example-image.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"example-image.jpg"},"id":"8835eac6-96fd-458f-a234-f0efcb86cb27","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"example-image3.jpeg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"example-image3.jpeg"},"id":"8262e2e8-4ed5-453e-9c3a-cbc2bbbfb7b0","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"malebody0051 (1).jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"malebody0051 (1).jpg"},"id":"d49cc57d-cb56-4f82-b555-4d821e6d397c","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"example-image2.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"example-image2.jpg"},"id":"ae3093c8-4778-4e2c-baaf-490114d8b690","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"image-application.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"image-application.jpg"},"id":"bf348f28-61ff-4dbb-ac35-f5aaea312180","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"swirlmachine2_0033.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"swirlmachine2_0033.png"},"id":"88026642-dbfa-452f-9b83-9e7a259d2cb6","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"image-technology.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"image-technology.jpg"},"id":"54beade6-82ec-4731-be81-d642cd944796","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"swirlmachine3_0033.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"swirlmachine3_0033.png"},"id":"6d6f531d-36fe-4e34-a017-3c128b479710","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"body_i2_0033.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"body_i2_0033.png"},"id":"e603e5cd-9ff5-45c3-ac88-6be9897529dc","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"malebody0051.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"malebody0051.png"},"id":"900552d0-b39a-47d1-b175-f7da0f1861ec","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"water.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"water.png"},"id":"4a0da4d4-b284-4ad7-9ce2-acd7e2e139fa","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"image-about.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"image-about.jpg"},"id":"c63e9143-aa0d-42af-9d88-33207bddbbb4","relationships":{},"type":"media"},{"attributes":{"contentType":"image/png","filename":"swirlmachine0000.png","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"swirlmachine0000.png"},"id":"2b1da7d3-bdf8-4604-9c5b-2a14b219b55c","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"20-069 Paul_Michielsen_Alfarim_Delft_Frame0001_H.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"20-069 Paul_Michielsen_Alfarim_Delft_Frame0001_H.jpg"},"id":"5d874a69-dbf1-49db-aedc-e447c62ecb8b","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"20-069 Paul_Michielsen_Alfarim_Delft_Frame0001_H.jpg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"20-069 Paul_Michielsen_Alfarim_Delft_Frame0001_H.jpg"},"id":"afe17ad0-80bf-406e-9800-995b7efe9fef","relationships":{},"type":"media"},{"attributes":{"contentType":"image/svg+xml","filename":"applications-image-03.svg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"applications-image-03.svg"},"id":"0037ca9e-b5f4-4d49-9d75-9856964270e3","relationships":{},"type":"media"},{"attributes":{"contentType":"image/svg+xml","filename":"infograph-03.svg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"infograph-03.svg"},"id":"b5e5e7b4-73eb-4311-bdc4-1eb7b010e828","relationships":{},"type":"media"},{"attributes":{"contentType":"image/svg+xml","filename":"infograph-01.svg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"infograph-01.svg"},"id":"ea35de26-3dfb-4109-af8f-48ff4ba034ed","relationships":{},"type":"media"},{"attributes":{"contentType":"image/svg+xml","filename":"infograph-02.svg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"infograph-02.svg"},"id":"cf86cb60-0aa4-4e65-8ec0-804314c7e92d","relationships":{},"type":"media"},{"attributes":{"contentType":"image/svg+xml","filename":"cancer-01 (1).svg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"cancer-01 (1).svg"},"id":"4cb4602c-2ef1-4bf7-ac32-680bb8f25dfb","relationships":{},"type":"media"},{"attributes":{"contentType":"image/svg+xml","filename":"cancer-02 (1).svg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"cancer-02 (1).svg"},"id":"6bab1c9c-b66a-4807-91cf-02b8ba09200d","relationships":{},"type":"media"},{"attributes":{"contentType":"image/jpeg","filename":"d49cc57d-cb56-4f82-b555-4d821e6d397c.jpeg","siteId":"e10ce892-0814-473b-8d19-2a0bc47986c3","title":"male body cropped"},"id":"c1b072f7-471e-41e9-a8b9-09d59d522a16","relationships":{},"type":"media"}],"included":[]}}}}